Last reviewed · How we verify
Matching placebo to sitagliptin — Competitive Intelligence Brief
phase 3
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
Matching placebo to sitagliptin (Matching placebo to sitagliptin) — Merck Sharp & Dohme LLC. This is a matching placebo control arm, not an active drug; it contains no pharmacologically active ingredient.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Matching placebo to sitagliptin TARGET | Matching placebo to sitagliptin | Merck Sharp & Dohme LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Matching placebo to sitagliptin CI watch — RSS
- Matching placebo to sitagliptin CI watch — Atom
- Matching placebo to sitagliptin CI watch — JSON
- Matching placebo to sitagliptin alone — RSS
Cite this brief
Drug Landscape (2026). Matching placebo to sitagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/matching-placebo-to-sitagliptin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab